|
1
|
Robinson E, Nandi M, Wilkinson LL,
Arrowsmith DM, Curtis AD and Richardson A: Preclinical evaluation
of statins as a treatment for ovarian cancer. Gynecol Oncol.
129:417–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Wolf E, Abdullah MI, Jones S, Menezes
K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA and
Richardson A: Dietary geranylgeraniol can limit the activity of
pitavastatin as a potential treatment for drug-resistant ovarian
cancer. Sci Rep. 7:54102017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukhtar RY, Reid J and Reckless JP:
Pitavastatin. Int J Clin Pract. 59:239–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ando H, Tsuruoka S, Yanagihara H, Sugimoto
K, Miyata M, Yamazoe Y, Takamura T, Kaneko S and Fujimura A:
Effects of grapefruit juice on the pharmacokinetics of pitavastatin
and atorvastatin. Br J Clin Pharmacol. 60:494–497. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung JY, Cho JY, Yu KS, Kim JR, Oh DS,
Jung HR, Lim KS, Moon KH, Shin SG and Jang IJ: Effect of OATP1B1
(SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin
in healthy volunteers. Clin Pharmacol Ther. 78:342–350. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hui CK, Cheung BM and Lau GK:
Pharmacokinetics of pitavastatin in subjects with child-pugh A and
B cirrhosis. Br J Clin Pharmacol. 59:291–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Labi V, Grespi F, Baumgartner F and
Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3
mimetics: A breakthrough in anticancer therapy? Cell Death Differ.
15:977–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Witham J, Valenti MR, De-Haven-Brandon AK,
Vidot S, Eccles SA, Kaye SB and Richardson A: The Bcl-2/Bcl-XL
family inhibitor ABT-737 sensitizes ovarian cancer cells to
carboplatin. Clin Cancer Res. 13:7191–7198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stamelos VA, Robinson E, Redman CW and
Richardson A: Navitoclax augments the activity of carboplatin and
paclitaxel combinations in ovarian cancer cells. Gynecol Oncol.
128:377–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abed MN, Abdullah MI and Richardson A:
Antagonism of Bcl-XL is necessary for synergy between carboplatin
and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 9:252016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghosh-Choudhury N, Mandal CC,
Ghosh-Choudhury N and Choudhury G Ghosh: Simvastatin induces
derepression of PTEN expression via NFkappaB to inhibit breast
cancer cell growth. Cell Signal. 22:749–758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS,
Cai DQ, Wu Z, Qin JW, Yu YH and Kim SK: HMG-CoA reductase
inhibitors induce apoptosis of lymphoma cells by promoting ROS
generation and regulating Akt, Erk and p38 signals via suppression
of mevalonate pathway. Cell Death Dis. 4:e5182013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Workman P, Clarke PA, Raynaud FI and van
Montfort RL: Drugging the PI3 kinome: From chemical tools to drugs
in the clinic. Cancer Res. 70:2146–2157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldoni M and Johansson C: A mathematical
approach to study combined effects of toxicants in vitro:
evaluation of the bliss independence criterion and the loewe
additivity model. Toxicol In Vitro. 21:759–769. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Richardson A, Malik RK, Hildebrand JD and
Parsons JT: Inhibition of cell spreading by expression of the
C-terminal domain of focal adhesion kinase (FAK) is rescued by
coexpression of Src or catalytically inactive FAK: A role for
paxillin tyrosine phosphorylation. Mol Cell Biol. 17:6906–6914.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kato S, Smalley S, Sadarangani A, Chen-Lin
K, Oliva B, Brañes J, Carvajal J, Gejman R, Owen GI and Cuello M:
Lipophilic but not hydrophilic statins selectively induce cell
death in gynaecological cancers expressing high levels of HMGCoA
reductase. J Cell Mol Med. 14:1180–1193. 2010.PubMed/NCBI
|
|
20
|
Taylor-Harding B, Orsulic S, Karlan BY and
Li AJ: Fluvastatin and cisplatin demonstrate synergistic
cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol.
119:549–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vidot S, Witham J, Agarwal R, Greenhough
S, Bamrah HS, Tigyi GJ, Kaye SB and Richardson A: Autotaxin delays
apoptosis induced by carboplatin in ovarian cancer cells. Cell
Signal. 22:926–935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miraglia E, Högberg J and Stenius U:
Statins exhibit anticancer effects through modifications of the
pAkt signaling pathway. Int J Oncol. 40:867–875. 2012.PubMed/NCBI
|
|
23
|
Hanrahan AJ, Schultz N, Westfal ML, Sakr
RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She
QB, et al: Genomic complexity and AKT dependence in serous ovarian
cancer. Cancer Discov. 2:56–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang J, Zhang L, Greshock J, Colligon TA,
Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al:
Frequent genetic abnormalities of the PI3K/AKT pathway in primary
ovarian cancer predict patient outcome. Genes Chromosomes Cancer.
50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robinson E, Fisher N, Stamelos V, Redman C
and Richardson A: New strategies for the treatment of ovarian
cancer. Biochem Soc Trans. 42:125–129. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie
L, Ma X, Wang J, Ouyang S, Wu Q, et al: Regulation of Mcl-1 by
constitutive activation of NF-κB contributes to cell viability in
human esophageal squamous cell carcinoma cells. BMC Cancer.
14:982014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Certo M, Del Gaizo Moore V, Nishino M, Wei
G, Korsmeyer S, Armstrong SA and Letai A: Mitochondria primed by
death signals determine cellular addiction to antiapoptotic BCL-2
family members. Cancer Cell. 9:351–365. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stamelos VA, Redman CW and Richardson A:
Understanding sensitivity to BH3 mimetics: ABT-737 as a case study
to foresee the complexities of personalized medicine. J Mol Signal.
7:122012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stamelos VA, Fisher N, Bamrah H, Voisey C,
Price JC, Farrell WE, Redman CW and Richardson A: The BH3 mimetic
obatoclax accumulates in lysosomes and causes their alkalinization.
PLoS One. 11:e01506962016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stamelos V: Investigation of the
BH3-mimetics navitoclax and obatoclax as potential therapeutics for
ovarian cancer. PhD thesisSchool of Pharmacy Keele University
Staffordshire: pp. 246ProQuest No. 1874909132. 2014
|
|
31
|
Del Gaizo Moore V and Letai A: BH3
profiling-measuring integrated function of the mitochondrial
apoptotic pathway to predict cell fate decisions. Cancer Lett.
332:202–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
